HYOGO, Japan, June 8, 2026
JCR Pharmaceuticals Co., Ltd. announced new clinical findings from its J-Brain Cargo® blood-brain barrier technology platform at the 18th International Symposium on MPS and Related Lysosomal Diseases held in Florence, Italy. The company presented updated data from its investigational therapies JR-171 (lepunafusp alfa) and JR-141 (pabinafusp alfa), highlighting progress in addressing the neurological complications of lysosomal storage disorders (LSDs). The findings reinforce JCR’s strategy of developing treatments capable of crossing the blood-brain barrier (BBB), a longstanding challenge that has limited the effectiveness of conventional enzyme replacement therapies for rare genetic diseases.
JR-171 Demonstrates Three-Year Safety and CNS Activity in MPS I
A key presentation focused on three-year results from a Phase I/II trial and extension study evaluating JR-171 (lepunafusp alfa) in patients with mucopolysaccharidosis type I (MPS I). The study enrolled patients across the Hurler, Hurler-Scheie, and Scheie disease spectrum and assessed both safety and pharmacodynamic outcomes. Researchers reported that weekly treatment maintained a favorable safety profile with treatment compliance exceeding 90% across dose groups. Importantly, no serious treatment-emergent adverse events were attributed to the investigational therapy. The study also demonstrated sustained reductions in cerebrospinal fluid heparan sulfate (CSF-HS) levels, providing evidence that JR-171 successfully crosses the blood-brain barrier and reaches the central nervous system. These findings support the therapy’s potential to address neurological manifestations of MPS I, an area of significant unmet medical need.
J-Brain Cargo Platform Addresses Critical Treatment Gaps
JCR’s proprietary J-Brain Cargo® platform is designed to transport biologic therapies across the blood-brain barrier through transferrin receptor-mediated delivery. Traditional enzyme replacement therapies effectively treat many systemic symptoms of lysosomal storage disorders but are unable to reach the brain, leaving progressive neurological decline largely untreated. By combining disease-specific enzymes with BBB-penetrating technology, JCR aims to deliver therapeutic benefit to both peripheral tissues and the central nervous system. According to the company, the latest JR-171 data further validate the platform’s ability to overcome one of the most significant barriers in rare disease drug development and may provide a foundation for future therapies targeting neurological complications of inherited metabolic disorders.
Advertisement
Long-Term Data Support JR-141 in Hunter Syndrome
JCR also presented additional analyses of JR-141 (pabinafusp alfa), marketed in Japan as IZCARGO™, for the treatment of mucopolysaccharidosis type II (MPS II or Hunter syndrome). Long-term pooled analyses involving up to five years of follow-up demonstrated sustained cognitive, adaptive behavior, and somatic benefits across a broad range of patient populations. Researchers reported that many patients experienced stabilization of neurological function or continued acquisition of developmental skills, particularly when treatment was initiated before irreversible neurodegeneration occurred. Additional findings showed positive effects on somatic disease manifestations across different age groups and disease severities, further supporting the therapy’s long-term clinical utility. The results add to growing evidence that BBB-penetrating enzyme replacement approaches may significantly improve outcomes for patients with Hunter syndrome.
Expanding the Pipeline for Rare Neurological Disorders
The presentations underscore JCR Pharmaceuticals’ commitment to advancing next-generation therapies for rare genetic diseases with neurological involvement. Beyond MPS I and MPS II, the company is developing additional investigational programs targeting disorders such as MPS IIIA and MPS IIIB (Sanfilippo syndrome) using its J-Brain Cargo platform. As regulatory agencies increasingly recognize the importance of addressing central nervous system manifestations in lysosomal storage disorders, JCR’s technology-driven approach positions the company at the forefront of innovation in rare disease therapeutics. The latest clinical findings provide encouraging evidence that BBB-penetrating biologics could reshape treatment paradigms for patients who currently have limited or no options for managing progressive neurological symptoms.
Source:JCR Pharmaceuticals press release
